Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

Official title

A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HSK42360 in Pediatric Patients With BRAF V600-Mutant Malignant Brain Tumors

Overview

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

Interventions

• Drug HSK42360
  Oral administration, QD/BID

Primary outcome measures

• MTD [Time frame: Up to approximately 52 months]
• DLTs [Time frame: Up to approximately 52 months]
• AEs [Time frame: Up to approximately 52 months]
• RP2D [Time frame: Up to approximately 52 months]
• Karnofsky/Lansky Performance Scale [Time frame: Up to approximately 52 months]

Secondary outcome measures (9)

• Overall response rate (ORR) [Time frame: Up to approximately 52 months]
• Disease control rate (DCR) [Time frame: Up to approximately 52 months]
• Duration of response (DOR) [Time frame: Up to approximately 52 months]
• Progression free survival (PFS) [Time frame: Up to approximately 52 months]
• Overall survival (OS) [Time frame: Up to approximately 52 months]
• Area under the curve (AUC) [Time frame: Circle 1 (28days)]
• maximum plasma concentration (Cmax) [Time frame: Circle 1 (28days)]
• half-life (t1/2) [Time frame: Circle 1 (28days)]
• Tmax(Time to maximum plasma concentration) [Time frame: Circle 1 (28days)]

Eligibility criteria

Inclusion criteria

• Age ≥6 and <18 years.
• Karnofsky/Lansky Performance Status >60.
• Life expectancy ≥ 3 months.
• Patients with recurrent malignant brain tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after treatment or intolerable treatment); patients who have previously received BRAF and/or MEK inhibitor therapy are allowed to be included in this study.
• Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.
• Patients will provide blood or tumor sample according to their own willingness.
• Measurable disease by RANO criteria.
• Patients with inactive CNS lesions, or patients treated with ≤5mg/day corticosteroid and without convulsion for ≥2 weeks.
• Adequate hematologic, hepatic, and renal function.
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose.

Exclusion criteria

• Patients with NF1 mutation.
• malignant tumor within 2 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low malignancy.
• Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol.
• Treatment with any of the following:

Prior treatment with anti-tumor drug within 4 weeks or approximately 5 × t1/2 prior to the first dose of HSK42360, whichever is shorter; Prior treatment with nitrosourea or mitomycin C within 6 weeks prior to the first dose of HSK42360; Prior treatment with palliative radiotherapy or anti-tumor herbs within 2 weeks prior to the first dose of HSK42360; Prior treatment with radiotherapy, electric field therapy, or other anti-tumor therapies within 4 weeks prior to the first dose of HSK42360.

• Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator.
• Any disease which would preclude drug absorption, metabolism or pharmacokinetics, eg. active peptic ulcer or chronic gastroesophageal reflux disease.
• Patient who have clinically significant or uncontrolled cardiac disease, include: QTc interval ≥ 450 msec; any clinically significant arrhythmia; left ventricular ejection fraction < 50%; myocardial infarction, unstable angina, or class III/IV cardiac failure by the NYHA that occurred within 6 months prior to the first dose of HSK42360.
• Any thromboembolic events within 6 months prior to the first dose of HSK42360; any familial or aquired thrombophilia.
• Any unstable systemic disease, eg. severe metabolic disease: liver cirrhosis, renal failure, or uremia.
• Treatment with inhibitors/inducers for CYP3A4, or substrates of CYP3A4, CYP2C9, CYP2C8, OATP1B1, OATP1B3, OAT1, OAT3, P-gp or BCRP within 14 days or approximately 5 × t1/2 prior to the first dose of HSK42360, whichever is shorter.
• Patient with cognitive dysfunction, or history of mental illness, other uncontrolled comorbidities, alcohol dependence, hormone dependence or drug abuse.
• Autologous transplantation surgery within 3 months prior to the first dose of HSK42360; Allogeneic transplantation, or stem-cell Transplant surgery within 6 months prior to the first dose of HSK42360; Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of HSK42360.
• Patient with a history of immunodeficiency, including HIV positive, or other acquired/congenital immunodeficiency diseases.
• Patient with severe retinal abnormalities and uveitis.
• Patient with active hepatitis B or hepatitis C.
• Allergic to any HSK42360 active constituent or ingredients.
• Participate in other clinical trials within 4 weeks prior to the first dose of HSK42360.
• Positive pregnancy test, or breastfeeding.
• Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 6 centers

• Xuanwu Hospital Capital Medical University — Beijing
• Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical Uni — Beijing
• The first affiliated hospital of fujian medical university — Fuzhou
• Zhujiang Hospital of Southern Medical University — Guangzhou
• The Third Bethune Hospital of Jilin University — Changchun
• Fudan University Affiliated Huashan Hospital — Shanghai

Identifiers

NCT: NCT07158710 · HSK42360-103

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗